Mucin Variable Number Tandem Repeat Polymorphisms and Severity of Cystic Fibrosis Lung Disease: Significant Association with MUC5AC by Guo, XL et al.
Mucin Variable Number Tandem Repeat Polymorphisms
and Severity of Cystic Fibrosis Lung Disease: Significant
Association with MUC5AC
XueLiang Guo1, Rhonda G. Pace1, Jaclyn R. Stonebraker1, Clayton W. Commander1, Anthony T. Dang1,
Mitchell L. Drumm2, Ann Harris3, Fei Zou4, Dallas M. Swallow5, Fred A. Wright4, Wanda K. O’Neal1.,
Michael R. Knowles1,6*.
1Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America,
2Departments of Pediatrics and Genetics, Case Western Reserve University, Cleveland, Ohio, United States of America, 3Human Molecular Genetics Program, Children’s
Memorial Research Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, 4Department of Biostatistics, University of
North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 5 Research Department of Genetics, Evolution and Environment, University College
London, London, United Kingdom, 6Gene Modifier Study Group, Chapel Hill, North Carolina, United States of America
Abstract
Variability in cystic fibrosis (CF) lung disease is partially due to non-CFTR genetic modifiers. Mucin genes are very
polymorphic, and mucins play a key role in the pathogenesis of CF lung disease; therefore, mucin genes are strong
candidates as genetic modifiers. DNA from CF patients recruited for extremes of lung phenotype was analyzed by Southern
blot or PCR to define variable number tandem repeat (VNTR) length polymorphisms for MUC1, MUC2, MUC5AC, and MUC7.
VNTR length polymorphisms were tested for association with lung disease severity and for linkage disequilibrium (LD) with
flanking single nucleotide polymorphisms (SNPs). No strong associations were found for MUC1, MUC2, or MUC7. A
significant association was found between the overall distribution of MUC5AC VNTR length and CF lung disease severity
(p = 0.025; n = 468 patients); plus, there was robust association of the specific 6.4 kb HinfI VNTR fragment with severity of
lung disease (p = 6.261024 after Bonferroni correction). There was strong LD between MUC5AC VNTR length modes and
flanking SNPs. The severity-associated 6.4 kb VNTR allele of MUC5AC was confirmed to be genetically distinct from the
6.3 kb allele, as it showed significantly stronger association with nearby SNPs. These data provide detailed respiratory mucin
gene VNTR allele distributions in CF patients. Our data also show a novel link between the MUC5AC 6.4 kb VNTR allele and
severity of CF lung disease. The LD pattern with surrounding SNPs suggests that the 6.4 kb allele contains, or is linked to,
important functional genetic variation.
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Introduction
Mucin glycoproteins are critically important in airway epithelial
biology and innate immunity [1]. For most mucins, the highly
glycosylated tandem repeat (TR) domain shows variation in repeat
number, and are referred to as VNTRs (variable number tandem
repeats) [2,3]. Large differences in VNTR sizes may alter mucin
protein molecular weight by as much as two-fold [4].
In the airways, secreted mucins (e.g. MUC5AC and MUC5B)
are key for mucociliary clearance, and transmembrane mucins
(e.g. MUC1 and MUC4) contribute to glycocalyx barrier function
[1,2]. Respiratory diseases, including cystic fibrosis (CF), asthma,
and chronic obstructive pulmonary disease (COPD), have
recognized alterations in normal mucin expression/properties that
contribute to pathophysiology [2]. In CF, defective ion transport
leads to dehydration of the airway surface liquid, reduced
mucociliary clearance, and susceptibility to chronic lung infections
[5].
Lung disease severity varies widely in CF, and at least 50% of
this variability is heritable [6]. Several genetic modifiers of CF lung
disease severity have been identified, but do not explain all of the
heritable variation [7–9]. Polymorphisms in respiratory mucins
could contribute to modifier effects, particularly variation in
VNTR length, which cannot be directly queried on panels used for
genome-wide association studies (GWAS).
We tested for association between CF lung disease severity and
VNTR length polymorphisms in mucin genes expressed in the
airway, which have been shown to have VNTRs. These were
MUC1, MUC2, MUC5AC and MUC7 whose encoded proteins are
of recognized importance in normal airway defense, and/or prior
studies that indicate they play a role in diseases of the lung, and
other inflammatory or malignant disease. There are reported
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25452
associations with VNTR length for MUC1 in lung adenocarcino-
ma, H.pylori gastritis and gastric carcinoma [10–12]; and MUC2
and MUC7 with asthma [13–15]. MUC5AC was chosen since it
encodes one of the two key secreted airway mucins that has a
VNTR [16,17], and it was hypothesized that this variation may
play an important, but as yet unidentified, role in airway disease
[1]. The other important airway secreted mucin, encoded by
MUC5B, has no common VNTR variation and thus was not tested
in this study. Using Southern Blot methods that define MUC5AC
allele lengths more precisely than previously reported [17–18], we
identified robust association of a specific MUC5AC VNTR allele
(6.4 kb, HinfI-digested DNA) and severe CF lung disease. For
MUC5AC and MUC1, we demonstrated significant linkage
disequilibrium (LD) between neighboring SNPs and VNTR alleles
categorized into size modes. Yet, even within modes, patterns of
association could separate alleles, and the MUC5AC 6.4 kb VNTR
allele was distinct from the 6.3 kb VNTR allele. These findings
highlight the complexity of genetic variation around mucin VNTR
regions and emphasize the need for further studies of individual
polymorphic alleles.
Methods
Additional detail is provided in the supporting information
(Text S1).
Ethics statement
This study was conducted with the approval of the University of
North Carolina at Chapel Hill Institutional Review Board and
informed written consent was received from all patients. The
manuscript does not contain identifying patient information. The
data were analyzed anonymously and all clinical investigations
have been conducted according to the principles expressed in the
Declaration of Helsinki.
Patient population
CF patients (Phe508del homozygotes), enrolled from extremes
of lung phenotype (‘‘severe’’ and ‘‘mild’’), were studied (Table S1).
These patients were classified as having either severe or mild lung
disease, as defined by the lowest or highest quartile of forced
expiratory volume in one second (FEV1), respectively, for age
[7,8].
Determination of VNTR allele sizes
To estimate VNTR allele sizes for MUC1, MUC2, and
MUC5AC genes, Southern blotting of HinfI-digested genomic
DNA was performed as described [18], with modifications to
improve resolution. To minimize gel-to-gel variation in allele size
identification, each gel included an internal DNA marker (mixture
of DNA from 3 CEPH cell lines; Coriell Cell Repositories,
Camden, New Jersey), which covered common MUC1, MUC2 and
MUC5AC VNTR alleles. MUC7 VNTR alleles were examined by
PCR.
SNP genotyping
Genotyping for VNTR flanking SNPs was conducted by
Applied Biosystems TaqManH SNP Genotyping Assays, Illumina
610-Quad [8] or Illumina Golden Gate platforms.
Statistical analysis
Differences in distributions of VNTR lengths between severe
and mild CF patients were assessed by non-parametric Wilcoxon
rank-sum tests (Intercooled Stata 10; College Station, TX). To
define ‘‘short’’ versus ‘‘long’’ alleles in a non-biased manner for
MUC1 and MUC5AC, which both have a bimodal distribution, we
estimated a finite mixture distribution using mixdist for the R
computing environment. Fisher’s exact or chi-square tests were
used to test for association between ‘‘VNTR genotypes’’ and
SNPs. Genetic associations between lung disease severity and
SNPs were conducted using PLINK v1.07 (http://pngu.mgh.
harvard.edu/purcell/plink/). Logistic regression, corrected for sex
and ten principal components, was conducted for each cohort.
HaploView version 4.2 was used to render LD maps. For two-
variant haplotype analysis, each combination was tested by
100,000 permutations, and analyzed in R using haplo.score. To
characterize the LD structure of SNPs associated with the 6.4 kb
MUC5AC allele versus the 6.3 kb allele, the haplo.em module within
the haplo.stats package was used (http://mayoresearch.mayo.edu/
mayo/research/schaid_lab/software.cfm) [19–22].
Results
Allele distributions
Southern blots (MUC1, MUC2, MUC5AC) and PCR (MUC7)
were used to estimate allele sizes (Figure S1), and allele
distributions for VNTR length polymorphisms are shown
(Figure 1). VNTR allele lengths were highly polymorphic. For
MUC1, allele sizes ranged from 2.6 to 8 kb. The distribution was
bimodal, with two relatively common peaks around 3.6 and 5.6 kb
(Figure 1A). For MUC2, allele sizes ranged from 3.7 to .8.5 kb;
however, the majority of alleles were between 5.9 to 7.2 kb,
distributed around the mode at 6.7 kb (Figure 1B). For MUC5AC,
alleles ranged from 5.6 to 8.5 kb, with a paucity of alleles
,6.25 kb, .7.0 kb, and between 6.60 to 6.85 kb. Larger size
alleles were relatively uncommon (Figure 1C). We observed two
alleles for MUC7 VNTRs, and the 5 repeat variant was infrequent
(,9%; Figure 1D).
Association of allele sizes to lung phenotype
We tested whether allele distribution was different between
patients with severe versus mild CF lung disease (Figure 2). There
was a trend toward significance for MUC1 (p = 0.079; Figure 2A)
but not for MUC2 (p = 0.143; Figure 2B) or MUC7 (p = 0.284;
Figure 2D). The MUC5AC association reached nominal statistical
significance (p = 0.025; Figure 2C), although this did not survive
correction for multiple comparison testing of 4 mucins (p = 0.1).
For MUC1, the trend was for larger alleles (.4.9 kb) to be more
common in mild CF patients. For MUC5AC, the difference in
allele distribution was driven by 6.30/6.35 kb alleles being more
prevalent in mild patients and 6.40/6.45 kb alleles more prevalent
in severe patients (Figure 2C).
Association by VNTR ‘‘genotype’’
For MUC1 and MUC5AC alleles, which had bimodal distribu-
tions (Figure 2A and 2C), we tested ‘‘short’’ (S) versus ‘‘long’’ (L)
alleles for association with CF lung disease severity. For MUC1,
because of the relatively continuous distribution of allele sizes, we
initially used a statistical mixture fitting approach and defined a
cut-point at 4.3 kb (S#4.3 kb,L) (Figure S2A), but saw no
association for allele-length genotypes and lung disease severity
(p = 0.337; Figure S3A). However, because the statistically
determined cut-point might not be most biologically relevant, we
also analyzed short and long VNTR allele genotypes using a
4.9 kb cut-point, which is closer to the average value for the two
most frequent alleles in the two modes of distribution, and which
were used in previous studies [11]. This analysis showed a stronger
trend for short alleles to be more common in severe patients, but
did not reach significance (p = 0.059; Figure S3B). For MUC5AC,
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the statistical mixture-fitting approach defined the cut-point at
6.7 kb (S,6.7 kb#L; Figure S2B), but no significant association of
VNTR length genotypes with lung disease severity was seen
(p = 0.914; Figure S3C).
We next considered the alternative hypothesis that individual
VNTR alleles could associate with lung disease severity, either
because they could contain functional variants, or act as proxies by
LD with other genomic variants. Thus, we tested each VNTR
allele individually for association with disease severity (only tested
alleles with frequency $4%; Table 1 and Table S2). No significant
association for MUC2 alleles was found (Table S2). Nominal
associations were found with the MUC1 3.7 kb and MUC5AC 6.35
and 6.30 kb alleles, but these did not survive correction for
multiple testing (Table S2 and Table 1). In contrast, there was
robust association between the MUC5AC 6.4 kb allele and severe
lung disease, when the 6.4 kb allele was considered as the
designated allele (D), versus all other alleles (p = 1.461025). This
strong association remained significant after Bonferroni correction
for all 44 tests conducted (p= 6.261024; Table 1).
SNP associations
Analysis of SNP data from candidate gene studies of MUC1,
MUC2, and MUC5AC showed that none of the genotyped SNPs
were highly associated with lung disease severity (Table S3). The
strongest association was with rs10902076, upstream of MUC2
(p = 4.561023), but the association did not survive correcting for
multiple comparisons (p = 0.068; Table S3), and replication studies
are needed to support this finding. Additionally, the larger GWAS
showed no significant associations with SNPs close to these mucin
genes [8].
Association of SNPs to VNTR allele sizes
We next characterized LD patterns of mucin VNTRs with
nearby SNPs. SNPs in high LD with VNTRs might be useful
proxies for VNTR alleles; plus LD structures would be useful for
other investigations involving mucin genes, since VNTR regions
cannot be adequately queried on current genotyping platforms.
Available MUC2 SNPs showed weak LD to MUC2 VNTR sizes,
whereas there was moderately strong LD between SNPs and
VNTRs for MUC7, similar to previously reported [15,23].
For MUC1 and MUC5AC, we tested for LD between flanking
SNPs and genotypes for VNTR allele genotypes, as defined above,
and the locations of SNPs (minor allele frequency .9%) and LD
status are shown (Figure 3).
MUC1. There was strong LD between flanking SNPs and
defined VNTR genotypes (S#4.9 kb,L), extending in both
directions from the VNTR. The strongest LD with VNTRs was
in the gene region between rs3814316 and rs2990245 (Figure 3A).
MUC5AC. The MUC5AC LD analysis was similar to MUC1 in
that strong LD was discovered between flanking SNPs and VNTR
Figure 1. Distributions of VNTR allele sizes. Distributions of VNTR allele sizes as determined by Southern blot analysis of HinfI-digested genomic
DNA are shown for (A) MUC1, (B) MUC2, (C) MUC5AC, and by polymerase chain reaction for (D) MUC7.
doi:10.1371/journal.pone.0025452.g001
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Figure 2. Distributions of VNTR allele sizes by lung severity status. Distributions of VNTR allele sizes by lung severity status for (A) MUC1, (B)
MUC2, (C) MUC5AC, and (D) MUC7 are shown. The number of chromosomes (alleles) representing each phenotype category for each mucin is given
(n), as is the Wilcoxon rank-sum test p value.
doi:10.1371/journal.pone.0025452.g002
Table 1. Association of MUC5AC VNTR allele sizes with lung disease severity (‘‘Severe’’ versus ‘‘Mild’’){.
D, D D, non-D non-D, non-D Fisher’s
n (%) n (%) n (%) Exact
Designated (‘‘D’’)
Allele Size (kb) Severe Mild Severe Mild Severe Mild P Value (nominal)
6.25 2 (1.0) 2 (0.7) 15 (7.7) 27 (9.9) 177 (91.3) 245 (89.4) 6.661021
6.30 20 (10.3) 44 (16.1) 67 (34.5) 105 (38.3) 107 (55.2) 125 (45.6) 7.361022
6.35 0 (0.0) 5 (1.8) 12 (6.2) 33 (12.1) 182 (93.8) 236 (86.1) 1.261022{
6.40 22 (11.3) 21 (7.7) 76 (39.2) 59 (21.5) 96 (49.5) 194 (70.8) 1.461025*
6.45 1 (0.5) 1 (0.4) 27 (13.9) 29 (10.6) 166 (85.6) 244 (89.0) 4.861021
6.50 4 (2.1) 4 (1.5) 8 (4.1) 13 (4.7) 182 (93.8) 257 (93.8) 8.661021
6.90 4 (2.1) 5 (1.8) 32 (16.5) 64 (23.4) 158 (81.4) 205 (74.8) 1.961021
7.00 0 (0.0) 4 (1.5) 18 (9.3) 19 (6.9) 176 (90.7) 251 (91.6) 1.761021
For each test, a specific size is denoted the ‘‘Designated’’ allele (allele D), and is compared to all other alleles (non-D). The number of patients (n = 468; Severe = 194;
Mild = 274) with each genotype (D, D; D, non-D; and non-D, non-D) is given for each test.
{Analyzed only for allele sizes that were present in $ 4% of the population.
{6.35 kb (and 6.30 kb) allele tends to associate with ‘‘mild’’ disease, but is not significant after Bonferroni correction.
*6.4 kb allele associates with ‘‘severe’’ lung disease; Bonferroni corrected p value for the tests indicated in this Table (8 tests total), p = 1.161024; corrected p value for
the tests in this Table, plus the original tests for association with lung disease severity shown in Figure 2 (12 tests total), p = 1.761024; corrected p value for all tests
directly above, plus the additional tests utilizing the cut-point analysis in Figure S3 (15 tests total), p = 2.161024; corrected p value for all tests directly above, plus the
MUC1 and MUC2 VNTR allele size tests for association (data not shown; 29 tests total), p = 4.161024; corrected p value for all tests directly above, plus SNPs in Table S3
(44 tests total), p = 6.261024.
doi:10.1371/journal.pone.0025452.t001
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genotypes (cut-point S,6.7 kb#L) (Figure 3B). However, unlike
MUC1, where very strong LD was found on both sides of the
VNTR region, LD for MUC5AC was strongest on the 39 side, in
the gene region between rs35705491 and rs13380. Within this LD
block, rs2075842 and rs28514396 are in near perfect LD, but
exhibit reduced LD to SNPs flanking either side (Figure 3B). These
SNPs are important in subsequent analyses to distinguish VNTR
alleles. SNPs between rs10902096 and rs17859811 (except
rs11245979) form a strong LD block, but this block is not in
significant LD with the VNTR S,6.7 kb#L genotypes.
Since the 6.4 kb allele of MUC5AC was associated with severe
CF lung disease, we next tested whether the severity-associated
6.4 kb allele could be distinguished from other alleles (especially
the 6.3 kb allele, which is similar in size and in frequency), based
upon LD patterns with nearby SNPs. In order to simplify the
comparisons for testing, we considered an artificial three-allele
system with VNTR alleles 6.3 kb and 6.4 kb treated separately,
and all other VNTR alleles collapsed into a single allele (Text S1).
We estimated the LD pattern of this three-allele VNTR with each
of the flanking SNPs, and then compared the strength of this
association to that observed when the VNTR was classified
according to an artificial two-allele system (6.3 kb/6.4 kb
combined into one allele versus all others). Likelihood ratio testing
of the VNTR three-allele system versus the two-allele system
showed highly significant evidence of improved fits from the three-
allele system (Figure 4), indicating that LD structure with nearby
SNPs was better explained by considering the 6.3 and 6.4 kb
alleles as separate alleles, rather than as the same allele (as in
Figure 3, where both alleles are grouped as ‘‘short’’). For many
SNPs in the region, the two alleles do act similarly (as indicated by
non-significant P-values in Figure 4); however, for other SNPs
(rs28514396; rs28678421; rs7120886), the pattern of association of
the 6.4 kb and 6.3 kb allele is clearly different (p = 2.03610211 for
rs28514396). This striking result easily meets multiple comparison
correction for the SNPs examined. In this manner, we provided a
rigorous test of a genetically meaningful difference between the
6.3 kb and 6.4 kb alleles, not only providing direct evidence of the
accuracy of the sizing on the Southern blot, but also providing
further evidence that the association of the 6.4 kb allele with CF
lung disease severity is deserving of careful follow-up.
Given these findings, we hypothesized that the phenotypic
association seen with the MUC5AC 6.4 kb allele could be
represented by extended haplotypes that included SNPs. We
inferred haplotypes and tested association for two-variant
haplotypes [22]. Haplotypes containing the 6.4 kb VNTR allele
had strong associations with severe CF lung disease, but
haplotypes that did not include the 6.4 kb allele, including those
that contained only SNPs, were not significant (Table S4). As
expected from the distribution analyses (Figure 2C), haplotypes
containing the 6.3 kb VNTR allele tended to be associated with
mild disease, but the associations were not robust. We conclude
that even though the 6.4 kb allele can be distinguished from other
VNTR alleles (Figure 4), the SNPs thus far tested do not clearly
tag the 6.4 kb severity-associated variant (Table S4).
Discussion
To evaluate the hypothesis that mucin gene VNTR polymor-
phisms are associated with severity of CF lung disease, we used
HinfI-digested DNA and Southern blot to determine the VNTR
allele length polymorphisms for MUC1, MUC2, and MUC5AC,
and used PCR methods for MUC7. Southern blot experiments
were carefully optimized to maximize the reliability of allele size
calls, using a mixture of samples from patients with ‘‘severe’’ and
‘‘mild’’ lung disease on each gel, standard internal markers and
size standards, and a genetically homogenous CF population
(Caucasian Phe508del homozygotes). Coupled with the availability
of SNP genotypes from larger studies [8], this current report
represents the largest and most comprehensive evaluation of
mucin VNTR regions available to date, and the first of its kind in
CF patients.
Our results confirm the polymorphic nature of VNTR regions,
as previously described [10,12,14,17]. The MUC1 allele distribu-
tion in our population was similar to that previously reported in
Europeans [12], but differs from that reported in Japanese [10],
who have fewer large size alleles and less distinct bimodal
distribution. The distributions of allele sizes, in our patients for
MUC2, MUC5AC, and MUC7, is similar to published work
Figure 4. Analysis of differential linkage disequilibrium
between MUC5AC 6.3 and 6.4 kb alleles versus nearby SNPs.
P values represent evidence of an improved fit to the LD patterns
between SNPs and the VNTR when 6.3/6.4 are treated as separate VNTR
alleles (three-allele system) instead of being collapsed into a single
allele (two-allele system). The p values represent a direct test of the
hypothesis that the 6.3 kb and 6.4 kb alleles follow distinct LD patterns
with the surrounding SNPs. Non-significant p values, e.g., those 59 to
MUC5AC, indicate that the two alleles share the same LD structure with
the SNPs, while significant p values indicate that the LD pattern
between the two alleles is different, e.g., at rs28514396. Approximate
location of HinfI fragment in MUC5AC shown in gray.
doi:10.1371/journal.pone.0025452.g004
Figure 3. Schematic representations of MUC1 and MUC5AC LD structure. The LD structure is shown for (A) MUC1 (n = 514 patients; human
genome build 19) and (B) MUC5AC genes (n = 468 patients; human genome build 18 was used due to incomplete build information in this region in
build 19). The location of the SNPs (minor allele frequency.9%) that have been evaluated are shown, along with their relative chromosome position.
The LD structure is shown, considering cut-points to assign genotypes for MUC1 (cut-point 4.9 kb; short#4.9 kb,long) and MUC5AC (cut-point
6.7 kb; short,6.7 kb#long). The plot was constructed with the Haploview program and the pairwise r2 (6100) values are depicted in the diamonds.
The dark diamonds have higher r2 ((6100) values, and the diamonds in lighter shade of color have lower r2 ((6100) values. The colored boxes above
the LD map represent the p value from chi-square tests to evaluate the significance of the SNP genotype to the VNTR allele genotypes. Color coding:
white (p.0.1), light blue (1025,p#0.1); medium blue (10210,p#1025); dark blue (10250,p#10210) and red (p#10250).
doi:10.1371/journal.pone.0025452.g003
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[14,17]; however, our data provide more fine detail. For example,
although both MUC1 and MUC5AC appear to have a ‘‘bimodal’’
distribution as reported previously, we demonstrated small
‘‘peaks’’ at 4.0 and 4.7 kb for MUC1 (Figure 1A) and large
clusters of alleles at 6.3 and 6.4 kb for MUC5AC (Figure 1C).
We initially hypothesized that the core VNTR length would
correlate with disease severity. While there was a trend toward
significance for MUC1 VNTR distribution to be different between
severe and mild patients, only the MUC5AC association reached
statistical significance (Figure 2C). However, when MUC5AC
VNTR alleles were classified into ‘‘genotypes’’ by size (short or
long alleles: S or L, respectively), there was not significant
association with disease severity by genotype (Figure S3C). Thus,
our initial hypothesis that VNTR size would be directly correlated
to phenotype was not confirmed. However, when we tested the
alternative hypothesis, i.e., that individual VNTR size variants
could associate with lung disease, we discovered a robust
association between the MUC5AC 6.4 kb VNTR allele and severe
lung disease (p = 6.261024 after Bonferroni correction; Table 1).
The availability of SNP genotype data in flanking regions
provided the opportunity to evaluate LD of SNPs with VNTR size
alleles. For both MUC1 and MUC5AC, there was strong
association between the VNTR genotype (short and long alleles;
Figure S2) and flanking SNPs (Figure 3), which is consistent with
previous results in smaller patient populations [24,25]. The SNPs
in strong LD could possibly be used as proxies for short/long
VNTR alleles, which may be useful for interpreting other GWAS
studies, if associations to MUC1 and MUC5AC SNPs are seen.
Flanking SNPs were also used to formally demonstrate that the
MUC5AC 6.4 kb allele is genetically distinct from other VNTR
alleles, particularly the 6.3 kb allele (Figure 4). The demonstration
that the 6.4 kb allele is genetically distinct ruled out technical
issues related to Southern blot resolution, and will enable future
efforts to define functional variants associated with the 6.4 kb
allele. None of the tested SNPs were able to strongly tag the causal
allele, and we were unable to define any SNP haplotypes that show
the same phenotypic association as the 6.4 kb allele. The genomic
structure of MUC5AC is poorly mapped and assembled in public
databases, and our lack of SNP association likely reflects the
paucity of pertinent SNPs available for genotyping. While the
possibility exists that the 6.4 kb allele association is due to a type 1
error (false positive), our findings support the concept that the
6.4 kb MUC5AC allele either contains or is linked to important
functional variants, some of which may be involved in diverse
functions outside those related to VNTR variants.
Functional variants in mucin genes are very likely in humans, as
polymorphisms within the amino acid motifs of the VNTR regions
are common [26,27], and alternative splicing also creates
potentially functional variations [28]. Amino-acid substitutions in
other regions may also affect function, for example, this has been
seen in mutant mice with colitis, where specific amino-acid
changes prevent proper processing and secretion [29].
To our knowledge, this is the first published association of
MUC5AC VNTR alleles with lung disease phenotypes. The odds
ratio for 1 or 2 copies of the 6.4 kb MUC5AC VNTR allele to be
associated with severe CF lung disease is 2.5. Extrapolating from
methods recently published [8,30], this translates to a difference in
the CF quantitative lung phenotype of 0.3 units, which equates to
an average difference of 7.7% in FEV1 (% predicted) between
adult patients that do not carry the 6.4 kb allele (n = 290) versus
those patients that carry one or two copies (n = 178). This is a
substantial adverse effect, resulting in an average difference in raw
FEV1 of ,275 ml, which is similar to values calculated for the
most significant association in the recently published GWAS study,
which queried a much larger CF population [8].
MUC5AC is a major mucin in airway secretions of healthy
subjects, and it is often up-regulated under a variety of pathogenic
conditions, including CF, COPD, smoking, and asthma [31–34].
The specific roles of MUC5AC in the normal lung, apart from other
secreted mucins, have not yet been fully defined, but it is reasonable
to speculate that it is involved in innate defense mechanisms
associated with mucociliary clearance. During disease, when innate
defense mechanisms are altered or fail, the presence of the correct
levels of MUC5AC of appropriate structure may be critically
important for airway defense. In a mouse model, Muc5ac was
recently shown to be a critical component in the immune regulated
rejection of enteric nematodes [35]. MUC5AC VNTR length
variants (which may confer differing structural properties), could
alter the function of the airway mucus, affecting the inflammation/
defense status and the progression of lung disease [1,2,16].
Alternatively, and/or additionally, the 6.4 kb allele may be
associated with some unknown genetic variants in the inaccessible
repetitive MUC5AC regions or other parts of the coding region, or
with regulatory variants that affect expression, as suggested for a
polymorphism inMUC5B, in a recent publication [36]. Whatever is
the case, the alleles described here might be relevant for other
serious lung diseases, and further studies to define the mechanistic
link between the MUC5AC VNTR functional variants and CF lung
disease are warranted.
Supporting Information
Figure S1 Representative Southern blots of HinfI-di-
gested genomic DNA. DNA was probed for MUC1 (A), MUC2
(B), and MUC5AC (C). PCR analysis of the MUC7 (D) repeat
polymorphism is shown. The MUC7 genotypes represent either 5
or 6 repeats of the VNTR. Heterozygotes have an additional
hetero-duplex band. M=molecular weight marker; M3=mixture
of CEPH DNA as described in Methods and Text S1.
(TIF)
Figure S2 Mixture fitting to define cut-points for short/
long alleles forMUC1 (A) andMUC5AC (B). The statistically
selected cut-points for each mucin are shown with the black
arrows, and they were taken as the average of two standard
deviations from the mean of the respective distributions. The
green lines represent the distribution trend with the two peaks
illustrating a bimodal mode. The blue lines represent the
distribution of the alleles. The red lines show all alleles calculated
with red arrows indicating the summit of each peak.
(TIF)
Figure S3 Genotype distribution by severity status for
VNTR length as defined by cut-points. The genotype
distribution by severity status for VNTR length is shown for
MUC1 (A) and MUC5AC (C), as defined by cut-point (see Figure
S2). Genotype distribution by severity status, based upon the
previously published defined cut-points (‘‘biological’’), is shown for
MUC1 (B). The number (n) of severe and mild patients is provided
for each analysis, as are the nominal p values (Fisher exact test).
(TIF)
Text S1 Supporting information text for Methods.
(DOC)
Table S1 Characteristics of CF patients used for VNTR
analysis.
(DOC)
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Table S2 Association of MUC1 and MUC2 VNTR allele
sizes with lung disease severity.
(DOC)
Table S3 Association of MUC1, MUC2 and MUC5AC
SNPs with CF lung phenotype.
(DOC)
Table S4 Two-variant haplotype analysis for 6.3 and
6.4 kb MUC5AC VNTR alleles with flanking SNPs.
(DOC)
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